Symbols

Symbols

Aime

Products

News

Markets

Watchlist

Brokers

News/

Stock/

BDTX

BDTX News

Newswire

09:05

Guggenheim Downgrades Black Diamond from Buy to Neutral

13:40

Black Diamond's Lung Cancer Drug Shows Promising Phase 2 Results with 60% Response Rate

07:07

Black Diamond Therapeutics reports silevertinib's 60% ORR in NSCLC patients.

03:50

Black Diamond to Present Phase 2 Data of Silevertinib in Non-Small Cell Lung Cancer

16:18

Black Diamond Therapeutics shares surge 15.25% after-hours after announcing Phase 2 silevertinib trial data webcast.

View More

About BDTX

Charts

--

Sector--

Established Date--

Listing Date--

Exchange--

Full-time Employees--

Fiscal Year Ends--

Website

Security Type--

Office address

Business

Introduction

View More